<DOC>
	<DOCNO>NCT02025608</DOCNO>
	<brief_summary>The purpose study explore whether patient restless legs syndrome ( RLS ) differ healthy subject daytime night time autonomic function cardiovascular risk marker whether 4 week treatment pramipexole affect autonomic function cardiovascular risk marker patient RLS .</brief_summary>
	<brief_title>Autonomic Function Cardiovascular Risk Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion Criteria ( participant ) : Willingness participate write informed consent Aged 30 65 year time screen Body mass index ( BMI ) ≤ 30 Unremarkable neurological physical examination Unremarkable standard blood parameter accord local reference value Additional Inclusion Criteria Restless Legs Syndrome ( RLS ) Patients : RLS accord current standard international criterion RLS symptom ≥ 2 time per week ≥ 1 year past 12 month . Either current international RLS severity scale ( IRLS ) ≥ 15 current IRLS ≥ 10 RLS symptom ≥ 4 time per week past 3 month . Exclusion Criteria ( participant ) : Pregnancy , breast feeding time screening . Recent anaesthesia ( last 3 month ) . Sleep relate breathe disorder nocturnal polysomnography : Current history psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders ( DSMIV ) . Life time history diagnosis , medication intervention cardiovascular disease . Current chronic treatment may affect autonomic function . Any significant neurological disease diagnose metabolic disease may affect cardiovascular function and/or increase cardiovascular risk . Any unstable medical condition . Smoking &gt; 5 cigarette per day last 2 year . Work involve night shift ( 22:00 06:00 h ) past 2 year . Travel &gt; 6 time zone difference past 6 month . Participation study involve investigational market product concomitantly within 3 month prior screen visit . Current participation clinical trial . Additional Exclusion Criteria RLS Patients Exposure dopaminergic drug &gt; 12 month life time and/or &gt; 1 week past 3 month and/or current past month . Exposure RLS relevant medication ( opioids , antiepileptic , clonidine except hypnotic benzodiazepine ) &gt; 24 month life time and/or &gt; 1 week past 3 month and/or current intake . Intake hypnotic ( benzodiazepine ) past month . Other significant sleep disorder except symptom potentially related RLS insomnia daytime sleepiness . Any contraindication know hypersensitivity dopaminergic drug . Additional Exclusion Criteria Control Subjects Any pharmacological treatment may affect sleep and/or sleep related movement disorder last 3 month . Any clinically significant sleep disorder accord International Classification Sleep Disorders ( ICSD ) 12 . Increased daytime sleepiness indicate Epworth Sleepiness Scale ( ESS ) score &gt; 11 .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Restless legs syndrome</keyword>
</DOC>